The Antidiabetic Effect of Mesenchymal Stem Cells Is Unrelated to Their Transdifferentiation Potential But to Their Capability to Restore Th1/Th2 Balance and to Modify the Pancreatic Microenvironment

Type 1 diabetes mellitus (T1DM) is a chronic metabolic disease that results from cell‐mediated autoimmune destruction of insulin‐producing cells. In T1DM animal models, it has been shown that the systemic administration of multipotent mesenchymal stromal cells, also referred as to mesenchymal stem cells (MSCs), results in the regeneration of pancreatic islets. Mechanisms underlying this effect are still poorly understood. Our aims were to assess whether donor MSCs (a) differentiate into pancreatic β‐cells and (b) modify systemic and pancreatic pathophysiologic markers of T1DM. After the intravenous administration of 5 × 105 syngeneic MSCs, we observed that mice with T1DM reverted their hyperglycemia and presented no donor‐derived insulin‐producing cells. In contrast, 7 and 65 days post‐transplantation, MSCs were engrafted into secondary lymphoid organs. This correlated with a systemic and local reduction in the abundance of autoaggressive T cells together with an increase in regulatory T cells. Additionally, in the pancreas of mice with T1DM treated with MSCs, we observed a cytokine profile shift from proinflammatory to antinflammatory. MSC transplantation did not reduce pancreatic cell apoptosis but recovered local expression and increased the circulating levels of epidermal growth factor, a pancreatic trophic factor. Therefore, the antidiabetic effect of MSCs intravenously administered is unrelated to their transdifferentiation potential but to their capability to restore the balance between Th1 and Th2 immunological responses along with the modification of the pancreatic microenvironment. Our data should be taken into account when designing clinical trials aimed to evaluate MSC transplantation in patients with T1DM since the presence of endogenous precursors seems to be critical in order to restore glycemic control. STEM Cells2012;30:1664–1674

[1]  F. Ezquer,et al.  Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome. , 2011, Journal of hepatology.

[2]  P. Fiorina,et al.  Immunological applications of stem cells in type 1 diabetes. , 2011, Endocrine reviews.

[3]  M. Yen,et al.  Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells , 2011, Journal of Biomedical Science.

[4]  Ariel Miller,et al.  Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. , 2011, Autoimmunity reviews.

[5]  F. Ezquer,et al.  The Antidiabetic Effect of MSCs Is Not Impaired by Insulin Prophylaxis and Is Not Improved by a Second Dose of Cells , 2011, PloS one.

[6]  M. Atkinson,et al.  Congenic Mesenchymal Stem Cell Therapy Reverses Hyperglycemia in Experimental Type 1 Diabetes , 2010, Diabetes.

[7]  C. Ricordi,et al.  Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes. , 2010, The review of diabetic studies : RDS.

[8]  S. González,et al.  Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. , 2010, Cytotherapy.

[9]  Torben F. Ørntoft,et al.  Cytokines Interleukin-1β and Tumor Necrosis Factor-α Regulate Different Transcriptional and Alternative Splicing Networks in Primary β-Cells , 2009, Diabetes.

[10]  M. Selig,et al.  Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes1 , 2009, The Journal of Immunology.

[11]  Qiu-ping Xie,et al.  Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. , 2009, Differentiation; research in biological diversity.

[12]  A. Eljaafari,et al.  Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells , 2009, Diabetologia.

[13]  C Dumitrache,et al.  Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes. , 2009, Diabetes & metabolism.

[14]  Yifan Dai,et al.  Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. , 2009, Journal of autoimmunity.

[15]  B. Hering,et al.  Upregulating CD4+CD25+FOXP3+ Regulatory T Cells in Pancreatic Lymph Nodes in Diabetic NOD Mice by Adjuvant Immunotherapy , 2009, Transplantation.

[16]  D. Wagner,et al.  Disruption of the homeostatic balance between autoaggressive (CD4+CD40+) and regulatory (CD4+CD25+FoxP3+) T cells promotes diabetes , 2008, Journal of leukocyte biology.

[17]  F. Ezquer,et al.  Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[19]  Annalisa Pasini,et al.  Immune Modulation by Mesenchymal Stem Cells , 2008, Transfusion Medicine and Hemotherapy.

[20]  N. Horwood,et al.  Potential of mesenchymal stem cell therapy , 2007, Current opinion in oncology.

[21]  D. Prockop,et al.  Concise Review: Mesenchymal Stem/Multipotent Stromal Cells: The State of Transdifferentiation and Modes of Tissue Repair—Current Views , 2007, Stem cells.

[22]  D. Prockop,et al.  “Stemness” Does Not Explain the Repair of Many Tissues by Mesenchymal Stem/Multipotent Stromal Cells (MSCs) , 2007, Clinical pharmacology and therapeutics.

[23]  D. Cui,et al.  Reversal of hyperglycemia in diabetic rats by portal vein transplantation of islet-like cells generated from bone marrow mesenchymal stem cells. , 2007, World journal of gastroenterology.

[24]  X. Hou,et al.  Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. , 2007, Chinese medical journal.

[25]  R. Cancedda,et al.  Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. , 2007, Arthritis and rheumatism.

[26]  Antonio Uccelli,et al.  Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis , 2007, Annals of neurology.

[27]  Darwin J. Prockop,et al.  Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice , 2006, Proceedings of the National Academy of Sciences.

[28]  A. Caplan,et al.  Mesenchymal stem cells as trophic mediators , 2006, Journal of cellular biochemistry.

[29]  Hanns-Ulrich Marschall,et al.  Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.

[30]  G. Mancardi,et al.  Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.

[31]  J. Lakey,et al.  Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass. , 2005, The Journal of clinical endocrinology and metabolism.

[32]  O. Pivetta,et al.  Early Manifestations in Multiple-low-dose Streptozotocin-induced Diabetes in Mice , 2005, Pancreas.

[33]  O. Ringdén,et al.  Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. , 2005, Experimental cell research.

[34]  G. Szot,et al.  Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. , 2004, The Journal of clinical investigation.

[35]  Fei Ye,et al.  Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. , 2004, The American journal of cardiology.

[36]  R. Tuan,et al.  Transdifferentiation potential of human mesenchymal stem cells derived from bone marrow , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  Douglas A. Melton,et al.  Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation , 2004, Nature.

[38]  D. Wagner,et al.  Peripheral CD4loCD40+ auto‐aggressive T cell expansion during insulin‐dependent diabetes mellitus , 2004, European journal of immunology.

[39]  S. Haynesworth,et al.  Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation , 2004, Bone Marrow Transplantation.

[40]  Lan Wang,et al.  No evidence for significant transdifferentiation of bone marrow into pancreatic beta-cells in vivo. , 2004, Diabetes.

[41]  A. F. Stewart,et al.  Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. , 2004, Endocrinology.

[42]  L. Adorini,et al.  Dynamics of Pathogenic and Suppressor T Cells in Autoimmune Diabetes Development , 2003, The Journal of Immunology.

[43]  M. Chopp,et al.  Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat , 2003, Journal of neuroscience research.

[44]  J. Bach.  Autoimmune Diseases as the Loss of Active “Self‐Control” , 2003, Annals of the New York Academy of Sciences.

[45]  R. Kawamori,et al.  Little evidence of transdifferentiation of bone marrow-derived cells into pancreatic beta cells , 2003, Diabetologia.

[46]  E. Guinan,et al.  Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.

[47]  S. Tågerud,et al.  Pharmacological treatment of chronic diabetes by stimulating pancreatic beta-cell regeneration with systemic co-administration of EGF and gastrin. , 2002, Pharmacology & toxicology.

[48]  E. Ayuso,et al.  β cell expression of IGF-I leads to recovery from type 1 diabetes , 2002 .

[49]  K. Haskins,et al.  Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Christophe Benoist,et al.  β-Cell death during progression to diabetes , 2001, Nature.

[51]  M. Atkinson,et al.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment , 2001, The Lancet.

[52]  R. Deans,et al.  Mesenchymal stem cells: biology and potential clinical uses. , 2000, Experimental hematology.

[53]  H. Nagawa,et al.  Characterization of intracellular cytokine profile of CD4(+) T cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer. , 2000, Japanese journal of clinical oncology.

[54]  D. Fedele,et al.  Evaluation of diagnostic reliability of DCA 2000 for rapid and simple monitoring of HbA1c , 2000, Acta Diabetologica.

[55]  B. Mroczkowski,et al.  Transgenic expression of epidermal growth factor and keratinocyte growth factor in beta-cells results in substantial morphological changes. , 1999, The Journal of endocrinology.

[56]  Darwin J. Prockop,et al.  Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta , 1999, Nature Medicine.

[57]  S. Paik,et al.  Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoimmune processes. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. Rossini,et al.  Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. , 1976, Science.

[59]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[60]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[61]  A. Cometa,et al.  Inherited thrombocytopenias: from genes to therapy , 1994 .

[62]  Yuval Dor,et al.  Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. , 2004, Nature.

[63]  Bart O. Roep Dr..  The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure , 2003, Diabetologia.

[64]  E. Ayuso,et al.  Beta cell expression of IGF-I leads to recovery from type 1 diabetes. , 2002, The Journal of clinical investigation.

[65]  C Benoist,et al.  beta-Cell death during progression to diabetes. , 2001, Nature.

[66]  E. Leiter.  Multiple low-dose streptozotocin-induced hyperglycemia and insulitis in C57BL mice: influence of inbred background, sex, and thymus. , 1982, Proceedings of the National Academy of Sciences of the United States of America.